Comparative Effectiveness of Anti-Obesity Drugs: BMJ | July 2026

Introduction:

The treatment of obesity has entered a new era with several highly effective pharmacological agents. This large systematic review and network meta-analysis compared the efficacy, safety, cardiovascular outcomes, and quality of life associated with currently available and emerging anti-obesity medications.

Why was this study needed?

• Numerous anti-obesity drugs are now available, but direct comparisons are limited.
• Clinicians need evidence to select the most effective and safest therapy.
• Long-term cardiovascular and metabolic benefits remain uncertain.
• Weight loss alone may not reflect overall clinical benefit.
• Comparative evidence is essential for shared decision-making.

Results:

• Tirzepatide and CagriSema produced the greatest weight loss, with emerging agents such as retatrutide, mazdutide, and ecnoglutide showing similarly promising efficacy.
• Greater weight loss was generally accompanied by higher rates of gastrointestinal adverse events and treatment discontinuation, emphasizing the balance between efficacy and tolerability.
• Subcutaneous semaglutide remains the only anti-obesity drug with proven reductions in all-cause mortality and myocardial infarction, while both semaglutide and tirzepatide reduced the risk of heart failure. No medication demonstrated convincing benefits for kidney failure or clinically meaningful improvements in quality of life.

Clinical Impact:

This comprehensive analysis highlights that not all weight-loss medications provide the same overall clinical benefit. Drug selection should consider cardiovascular protection, adverse effects, patient preferences, comorbidities, and long-term treatment goals, rather than weight loss alone.

Bottom Line:

Tirzepatide currently provides the greatest weight loss, whereas semaglutide has the strongest evidence for cardiovascular benefit. Choosing the optimal anti-obesity therapy requires balancing efficacy, safety, long-term outcomes, and individual patient priorities through shared decision-making.